Samsung Biologics Boosts Renewable Energy Use, Expands ESG Reporting
Event summary
- Samsung Biologics increased its renewable energy transition rate to 39.8% under its RE100 roadmap.
- Scope 3 greenhouse gas emissions reporting coverage expanded from 56.3% to 63.7%.
- The company achieved third-party validation of its product carbon footprint (PCF) methodology.
- Supplier sustainability assessments and engagement programs reached 57.3% participation.
The big picture
Samsung Biologics is aligning its operations with evolving ESG standards, particularly as regulatory frameworks like the European Sustainability Reporting Standards (ESRS) gain traction. The company's focus on renewable energy and supply chain resilience reflects broader industry trends toward sustainable healthcare value chains. With a global manufacturing capacity of 845,000 liters, Samsung Biologics is positioning itself as a key player in the biopharmaceutical sector's transition to lower-carbon operations.
What we're watching
- Renewable Energy Transition
- How Samsung Biologics will accelerate its renewable energy transition to meet RE100 targets.
- Supply Chain Engagement
- Whether the company can sustain and expand supplier sustainability assessments beyond 57.3%.
- Industry Collaboration
- The pace at which Samsung Biologics' participation in the Sustainable Markets Initiative (SMI) Health Systems Task Force drives industry-wide sustainability goals.